Ponezumab

Phase 2Monoclonal antibody

Pfizer

Ponezumab is one of 8 biologic programs targeting Cerebral Amyloid Angiopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral Amyloid AngiopathyActive, not recruiting

Cerebral Amyloid AngiopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Cerebral Amyloid Angiopathy

#DrugCompanyPhaseTrials

Minocin

TTriax

Approved

—2

Colcrys

Alnylam Pharmaceuticals

Phase 2

1 3

Amyloid PET

NNational Taiwan University Hospital

Phase 3

1 4

RG6026

Plavix

Bayer Aspirin

ALN-APP

Alnylam Pharmaceuticals

Phase 2

1 8

Ponezumab

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cerebral Amyloid Angiopathy1 trial

Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

Completed· Pfizer logo

Pfizer·Phase 2·NCT01821118·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ponezumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ponezumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ponezumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Ponezumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cerebral Amyloid Angiopathy1 trial

References

Drug Info

Quick Facts

Related News